专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017087962A1 METHODS FOR TREATING ALZHEIMER'S DISEASE AND RELATED DISORDERS 审中-公开
标题翻译：治疗阿尔茨海默病和相关病症的方法
公开(公告)号：WO2017087962A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/063143
申请日：2016-11-21
申请人： AZTHERAPIES,INC.
发明人： ELMALEH, David
IPC分类号： A61K51/04 , C07D311/24
CPC分类号： A61K31/352
摘要： The invention is directed to a method of treating Alzheimer's Disease by administering to a subject in need thereof a therapeutically effective amount of cromolyn and optionally ibuprofen. The cromolyn may be in the form of cromolyn sodium and administered by inhalation.
摘要翻译：本发明涉及通过向有需要的受试者施用治疗有效量的色甘酸和任选的布洛芬来治疗阿尔茨海默氏病的方法。色甘酸可以是色甘酸钠的形式并通过吸入给药。

2. 发明申请

WO2019017995A1 POWDERED FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN 审中-公开
公开(公告)号：WO2019017995A1
公开(公告)日：2019-01-24
申请号：PCT/US2017/065727
申请日：2017-12-12
申请人： AZTHERAPIES, INC.
发明人： ELMALEH, David, R. , GONZALEZ, Juan, B.
IPC分类号： A61K9/14 , A61K31/33 , A61P25/28
摘要： The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 μm sieve and to methods of making the same.

3. 发明申请

WO2015002703A1 METHODS FOR DELIVERING CROMOLYN 审中-公开
标题翻译：交付CROMOLYN的方法
公开(公告)号：WO2015002703A1
公开(公告)日：2015-01-08
申请号：PCT/US2014/039118
申请日：2014-05-22
申请人： AZTHERAPIES, INC
发明人： ELMALEH, David, R. , FRANZUSOFF, Alex
IPC分类号： A01N43/16
CPC分类号： A61K31/352 , A61K9/0075 , A61K9/145 , A61K31/192 , A61K45/06 , A61K2300/00
摘要： Methods of delivering cromolyn to a patient in need thereof methods of treating amyloid-associated conditions and inflammatory or aliergic lung diseases, and blister packs and kits comprising cromolyn are described.
摘要翻译：向有需要的患者提供色甘酸的方法描述了治疗淀粉样蛋白相关病症和炎性或致病性肺部疾病的方法，以及包含色甘酸的起泡包装和试剂盒。

4. 发明申请

WO2021243275A2 CAR-TREG-BASED THERAPIES TARGETING MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) FOR TREATING NEURODEGENERATIVE DISEASES 审中-公开
公开(公告)号：WO2021243275A2
公开(公告)日：2021-12-02
申请号：PCT/US2021/034968
申请日：2021-05-28
申请人： AZTHERAPIES, INC.
发明人： WATKIN, Levi, B. , ASHTON-RICKARDT, Philip, G.
IPC分类号： C07K16/28 , A61K39/00 , C07K14/725 , A61K2039/5156 , A61K38/1709 , C07K14/7051 , C07K16/2803 , C07K2317/622 , C07K2319/03 , C07K2319/43
摘要： The invention provides compositions and methods for suppressing autoimmune components of neurodegenerative diseases and thereby providing therapeutic effects to patients suffering from such diseases, Compositions and methods include immunosuppressive moieties such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or protein that specifically binds one or more glial cell markers. Therapeutically effective doses of said compounds for treating neurodegenerative diseases including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), multiple sclerosis, and prion diseases are disclosed.

5. 发明申请

WO2020010049A1 POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE 审中-公开
公开(公告)号：WO2020010049A1
公开(公告)日：2020-01-09
申请号：PCT/US2019/040247
申请日：2019-07-02
申请人： THE GENERAL HOSPITAL CORPORATION , AZTHERAPIES, INC.
发明人： ELMALEH, David, R. , GONZALEZ, Juan, B.
IPC分类号： A61K31/277 , A61K31/352 , A61K31/4422
摘要： The present disclosure is directed to a composition comprising micronized cromolyn sodium, α-lactose, and a salt of fatty acid, wherein the α-lactose has a particle size distribution of D 90 of 45-70 μm, D 50 of 10-35 μm, and D 10 of 2-13 μm. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

6. 发明申请

WO2017091644A1 COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC STROKE 审中-公开
标题翻译：治疗缺血性中风的组合物和方法
公开(公告)号：WO2017091644A1
公开(公告)日：2017-06-01
申请号：PCT/US2016/063462
申请日：2016-11-23
申请人： AZTHERAPIES, INC.
发明人： ELMALEH, David
IPC分类号： A61K31/192 , A61K31/352
CPC分类号： A61K31/192 , A61K31/352 , A61K2300/00
摘要： The invention is directed to methods of treating ischemic stroke by adminis-tering a therapeutically effective amount of at least one compound of Formula I or Formula II to a subject in need thereof, wherein the compound has Formula I or Formula II: or a salt or ester of (I) or (II); wherein X is OH, C 1 -C 6 alkoxyl, 18 F, or 19 F; Y and Z are independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, halogen, substituted or unsubstituted C 1 -C 6 amine, 18 F, 19 F, or H; and n is 1, 2, or 3.
摘要翻译：本发明涉及通过给有此需要的受试者施用治疗有效量的至少一种式I或式II的化合物来治疗缺血性中风的方法，其中所述化合物具有式I 或式II：或（I）或（II）的盐或酯; 其中X是OH，C 1 -C 6烷氧基，18 F或19 F; Y和Z独立地选自C 1 -C 6烷基，C 1 -C 6烷氧基，卤素，被取代的或未被取代的C 1 -C 6胺，18 F，19 F或H; 而n是1,2或3。

7. 发明申请

WO2021216978A1 CELLULAR ABLATION OF HLA-CLASS I MHC 审中-公开
公开(公告)号：WO2021216978A1
公开(公告)日：2021-10-28
申请号：PCT/US2021/028808
申请日：2021-04-23
申请人： AZTHERAPIES, INC.
发明人： ASHTON-RICKARDT, Philip, G.
IPC分类号： C12N15/113 , C12N15/86 , C07K14/725 , A61K31/7088 , A61K35/17
摘要： The invention provides compositions and methods for reducing the immunogenicity of cells for transplant including cell-based immunotherapies. Vectors encoding beta 2 microglobulin (B2M) modifying RNAs along with targeting moieties and other signaling and/or suicide genes allow for efficient production of engineered CAR T-regulatory or other therapeutic cells from any source.

8. 发明申请

WO2020214538A1 TREATMENT AND PREVENTION OF DEMENTIA AND OTHER NEURODEGENERATIVE DISEASES 审中-公开
公开(公告)号：WO2020214538A1
公开(公告)日：2020-10-22
申请号：PCT/US2020/027988
申请日：2020-04-13
申请人： AZTHERAPIES, INC
发明人： ELMALEH, David R.
IPC分类号： G01N33/569 , G01N33/68 , C12Q1/689 , A61K39/00 , A61K38/00
摘要： The present invention relates to pharmaceutical compositions and methods for the treatment or prevention of dementia and decreased function associated with neurodegenerative disease including Alzheimer's disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), including at the early stages of cognitive and functional decline with antibiotics and synthetic anti-bacterials, by administering to a subject a pharmaceutical composition comprising a chronic low-dose antibiotic administration, optionally as adjuvant and/or with a co-therapy, such as an innate immune modulator; an anti-inflammatory agent; a neurotransmitter; an acetylcholine esterase (AChEI) inhibitor; an enzyme inhibiting or reducing the production, aggregation, or deposition of amyloid-beta protein, amyloidosis or tau protein; an antibody inhibiting or reducing the production, aggregation, deposition or removal of amyloid-beta protein or tau protein; melatonin; an antimicrobial adjuvant; lichen compounds, astemizole, or polythiophenes; mannitol, a nanoparticle, a vasodilator, or a glucose or amino acid carrier; or a combination thereof. The present invention also relates to treatment that focuses on delaying neurodegeneration associated with AD, PD, ALS and the like by targeting specific microbe profiles associated with the disease in gastrointestinal tract (gut) or brain and suppressing their effect on neuroinflammation by low dose chronic treatment alone and/or in combination with other disease treatments or supporting additives.

9. 发明申请

WO2020051322A1 METHODS OF TREATING CYTOKINE RELEASE SYNDROME 审中-公开
公开(公告)号：WO2020051322A1
公开(公告)日：2020-03-12
申请号：PCT/US2019/049733
申请日：2019-09-05
申请人： THE GENERAL HOSPITAL CORPORATION , AZTHERAPIES, INC.
发明人： ELMALEH, David, R. , TANZI, Rudolph, E. , GRICIUC, Ana , WARREN, Robert , REEVES, Karen
IPC分类号： A61K31/352 , C07D311/24
摘要： The present disclosure relates to a method of treating at least one condition selected from Cytokine Release Syndrome (CRS), Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R 1 is halogen, OH, or -OC(O)C 1-5 alkyl R 2 and R 3 are each independently selected from CO 2 R 4 or CH 2 OR 5 ; R 4 is Li, Na, K, H, C 1-5 alkyl, or -CH 2 CO(C 1-5 alkyl); and R 5 is H or –C(O)(C 1-5 alkyl), or a pharmaceutically acceptable salt thereof.

10. 发明申请

WO2019112552A1 CROMOLYN COMPOSITIONS AND METHODS THEREOF 审中-公开
公开(公告)号：WO2019112552A1
公开(公告)日：2019-06-13
申请号：PCT/US2017/064526
申请日：2017-12-28
申请人： AZTHERAPIES, INC , ELMALEH, David R.
发明人： ELMALEH, David R.
IPC分类号： A61K31/192 , A61K31/352 , A61K9/14
CPC分类号： A61K31/352 , A61K9/0075
摘要： Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式